Link to this page
Biological and Environmental Research Ontology
| Id | http://purl.obolibrary.org/obo/NCIT_C79833
http://purl.obolibrary.org/obo/NCIT_C79833
|
|---|---|
| Preferred Name | Olvimulogene Nanivacirepvec |
| Definitions |
An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An attenuated oncolytic vaccinia virus encoding the light-emitting fusion protein Renilla luciferase-Aequorea green fluorescent protein (RUC-GFP) with potential bioluminescent and antineoplastic activities. Upon administration, light-emitting oncolytic vaccinia virus GL-ONC1 specifically enters tumor cells due to the permeable nature of the tumor vasculature. Once inside the cell, the virus replicates, resulting in tumor cell lysis and the release of mature viral particles into the tumor microenvironment. Released viral particles may then infect and destroy neighboring tumor cells. In addition, the release of tumor-associated antigens (TAAs) by lysed tumor cells into the bloodstream may activate the immune system to mount a cytotoxic T lymphocyte (CTL) response against the tumor. The expression of RUC-GFP by this agent allows for both detection and monitoring of virally infected tumor cells in vivo and vitro with luciferase-mediated bioluminescence imaging and fluorescence imaging techniques. |
|---|---|
| label | Olvimulogene Nanivacirepvec
|
| prefLabel | Olvimulogene Nanivacirepvec
|
| Legacy Concept Name | Light-Emitting_Oncolytic_Vaccinia_Virus_GL-ONC1
|
| in_subset |
See more
See less
|
| Preferred_Name | Olvimulogene Nanivacirepvec
|
| Is_Value_For_GDC_Property | |
| Display_Name | Olvimulogene Nanivacirepvec
|
| Maps_To |
Olvimulogene Nanivacirepvec
Light-Emitting Oncolytic Vaccinia Virus GL-ONC1
|
| PDQ_Open_Trial_Search_ID | 629379
|
| FDA_UNII_Code | CF19SF72O5
|
| prefixIRI | NCIT:C79833
|
| NCI_Drug_Dictionary_ID | 629379
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C79833
|
| type | |
| PDQ_Closed_Trial_Search_ID | 629379
|
| Semantic_Type | Pharmacologic Substance
|
| CAS_Registry | 1473430-36-2
|
| NCI_META_CUI | CL388438
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |